Olema Pharmaceuticals, Inc. · NASDAQ:OLMA
Olema Pharmaceuticals — Investor Presentation (May 2023)
37 slides from Olema Pharmaceuticals's investor presentation, May 11, 2023
Slide 1: - -
- -
Slide 2: Forward-looking statements
$&+&2 $$ #(("#(' ( %'(#))$# $#)#( $','8!$$ # ())"#)( " %*'(*#) )$ ) ( '$' %'$+($#( $ ) '+) *')( ))$# $'" -) $ BJJF3 ))"#)( # )( %'(#))$# )) ' #$) ())"#)( $ ()$'! ) ' $','8!$$ # ())"#)(3 * $',
Slide 3: #(,(#&($#$&!-1'$&(&("#($ =1 2 ('((&'(#&3 4 05694+…
#(,(#&($#$&!-1'$&(&("#($ =1 2 ('((&'(#&3 4 05694+!% % $%0 0$$- /!# =/60 "&!#"!% !" " ! "%&!%%" 4(.) " &)!$ ' %&)%
Slide 4: '!#! ( ( ( !## -))%( -2351 :, 3- $#$$"#$" :1; ! "!"'%#,
'!#! ( ( ( !## -))%( -2351 :, 3- $#$$"#$" :1; ! "!"'%#, 3*'!*'"(' '&'&&4 &;!''"!: :8:; " "%#,*' <1>#" &:+#!&"!"!"! " "%#,*' <1>%" &9"&&'"
Slide 5: &'(#&'($# $'( $""$##$'#&$&!+ #"!$ "**&" "$ !##…
&'(#&'($# $'( $""$##$'#&$&!+ #"!$ "**&" "$ !## " "!"" !" '$(3%'" ")'$/)%$2-#'$$'%).4)($*'(@>@@2)( 7577*""#!(%) !%% "**%
Slide 6: 263!%&$","-&$","-* %&!.273 -#"-$".283"#!%.293%$" '%- (…
263!%&$","-&$","-* %&!.273 -#"-$".283"#!%.293%$" '%- ($" '%-& %$" '% - - -
Slide 7: ! "#('$&%-#=1 92 &'(#& ><>A$$&(% *%$)*#*)4"#$*($"*1 $%(#…
! "#('$&%-#=1 92 &'(#& ><>A$$&(% *%$)*#*)4"#$*($"*1 $%(#F5 >6 (,"$) (!*%()*4:>D"()!'#'!'&&&( '") 2>?G:8D0%, %&'!%!!!(&%&()!'& !'4><>A
Slide 8: " ##(!-+&$"%(#&$&"'$&91: #8 &("#( 76-') %#%!& 8687 :-')%#%!…
" ##(!-+&$"%(#&$&"'$&91: #8 &("#( 76-') %#%!& 8687 :-')%#%!&8688 ( $) 0$ (% ' 0$ (% <-')%#%!&8687 :-') %#%!&8688 4 ;$'$5( '*"()'$) ,(&&'%+.)44-%$ $*'.@E1@>@A4
Slide 9: # 289;7/'(2#2!''$(#(!$&=1 92 &'(#& %#%! -%%#%' #! ! %*(/…
# 289;7/'(2#2!''$(#(!$&=1 92 &'(#& %#%! -%%#%' #! ! %*(/ 8/: - - # !" $
Slide 10: ! - !!"
! - !!"
Slide 11: /67:5 $6!$$%! $7!$(" $! . ! / '819$"#($#()-+(!$!/()-…
/67:5 $6!$$%! $7!$(" $! . ! / '819$"#($#()-+(!$!/()-'# + " (&#"%'%. E3 =4 ,%()*%( ,#+#))5$)+(#%%&%4$)+(#6 G<'(&(&($&%#($%&(#&##/,%&($*)**
Slide 12: 289;7'819#$"#($#+(!$! -2 !! '-+/)1!!!'//5$! …
289;7'819#$"#($#+(!$! -2 !! '-+/)1!!!'//5$! ,"!! $$"$"#$# $ 3 F:A4 32 16(43 - $ - .6)33* .. .-)01* $ /0)46*
Slide 13: 289;7'819#$"#($#+(!$! !$! ( *! - …
289;7'819#$"#($#+(!$! !$! ( *! - -&"D75A# '"'& /67:5#& #B( )&'%"' 85!0"C81 ;5!0"C81 >5!0"C81 675!0"C751 - 0"C7>1 #!/80"C89:1 - %& % D8 - %& % D
Slide 14: 289;7'819()-#$"#($#+(!$! % "# - #…
289;7'819()-#$"#($#+(!$! % "# - # - $ #!- - - " % "$'0$'!&$&"!2 3&)! #" !089
Slide 15: 289;7'819()-#$"#($#+(!$! *,-0+% "# ! !…
289;7'819()-#$"#($#+(!$! *,-0+% "# ! !& $ #!- - " - "$'0$'!&$&"!2 3&)! #" !089
Slide 16: 289;7'819#$"#($#+(!$! && !!!*!& , "!…
289;7'819#$"#($#+(!$! && !!!*!& , "!! !! -&(&+ "!%&$&!"& )&+#!8 #&!&% $&$%#"!%%)$"%$(! (#&!&%&"&2"!"!$ . "'$'!"!$ 3 !!
Slide 17: ! '8$"#($#()-+($! #-!%!' 7 CC 2 :0<") #%$%)#(& + '%'3 …
! '8$"#($#()-+($! #-!%!' 7 CC 2 :0<") #%$%)#(& + '%'3 '"'&*' 9 !(''#" 8178;6C # <66! 8178;6C - $ &966! # <66! - $ & 966! !$$%! !$(" $! !% #$
Slide 18: " %"& -&$&&
" %"& -&$&&
Slide 19: # 289;72778&'(2#2 )"#'819 $#$(&%-()-/()-'# ')&2-%*4*+$&(*,*/% $)+(#…
# 289;72778&'(2#2 )"#'819 $#$(&%-()-/()-'# ')&2-%*4*+$&(*,*/% $)+(#))&&(*1)*/% *&#(#*/*= %!%,#')&2($&"%*)1)*/%*&#(#*/1%*/= #"%,#')&25E615EE
Slide 20: 289;7'819$',%#'$# !! #%! # =@C"#&!&%$( 9"$ "$#…
289;7'819$',%#'$# !! #%! # =@C"#&!&%$( 9"$ "$#$"$!%" &$#+!&(! %&&!.?9C(%$ %% @=C$(#$"$ ;/=.?8C$( #$"$- ..=<C$( #$"$'(%&$!& <@C&(&! '&
Slide 21: $'2&$%$&($#! +(%("!(-2((!'"$##(&($#' )"!"$G*(*%+).&%)+(…
$'2&$%$&($#! +(%("!(-2((!'"$##(&($#' )"!"$G*(*%+).&%)+() %$ )*(%"6)+&&"#$*&("$"#%") 7G>>B$5# 87D)*+)82%**("$G+",)*($* G>D#%)*A<<#,(/>D/) 1%$"/4 !-'%#&
Slide 22: <7"#897"$''!!$!&(#'819 $#$(&%- $',%#'$# -&"D6:A #'"'&"&…
<7"#897"$''!!$!&(#'819 $#$(&%- $',%#'$# -&"D6:A #'"'&"&6.6 ;5! 0"C881 675! 0"C8:1 #' 0;5!2675!-"C;=1 %6 %7 D%8 %6 %7 D%8 %6.7 D%8 -%/- D B < <C > A 8<0:9A1 <065A1 +) C = ;
Slide 23: ##)!-#(2)"$&-(*(-#289;7$',%#'$# *$* $+$%$(#&(*"()&%$)$"*(&(%…
##)!-#(2)"$&-(*(-#289;7$',%#'$# *$* $+$%$(#&(*"()&%$)$"*(&(%())*)+)'+$*)$4 (! )%.)$*#+**%$&()$*1"*)%.)$*-"6*/&1$*)$%%.$*)#))$*4 - 1(%#*)$
Slide 24: !&-#)&!!#!#(# *!-&(&($%)!($# %" %.)$*#+**%$&(…
!&-#)&!!#!#(# *!-&(&($%)!($# %" %.)$*#+**%$&()$*1%&$%.)$*-"6*/&1$*)$%%.$*)#))$*4 9$%$(#&(*"()&%$))-*$%$(#*%$*)+)'+$*)$4 - 1(%#*)$*%
Slide 25: '819$',%#'$#)""&- *,-0+ .*& !$! !** 5!"!% …
'819$',%#'$#)""&- *,-0+ .*& !$! !** 5!"!% #%'%&#"!&&*'!"!% '"!'&(&$(!'&!0 55"(%/ - &;'%! <1>!'"%2+#%!:1; #'!'&. "(%!"!!"",0 '('&
Slide 26: *!$&(&("#( "%(',%(-#9 ==1 92 …
*!$&(&("#( "%(',%(-#9 ==1 92 - "'$/$ %'## !&"' !&%7577 . !&"(756:0 7</< !# 7/? !# "!28 3 $29 D3 *'0 &'$%# % #.7 A! !%#")/
Slide 27: ! - '
! - '
Slide 28: " %!--*##289;7$+&*$(!':()' , "!"&$#+ %8"%%&"! %8…
" %!--*##289;7$+&*$(!':()' , "!"&$#+ %8"%%&"! %8"%*#!%"! #&+$"&#"';5!"675! #!$ '"%# !"'"C:; %9 )+(# )) &%4$)+(# )) *) 4 +5 $" !5 #!$ '"%# !"'"C:
Slide 29: # !*&#$#!)&(# !'($#'#979: %#! $"!$%! !26<;,5 ! %!$&""!#% '!" %…
# !*&#$#!)&(# !'($#'#979: %#! $"!$%! !26<;,5 ! %!$&""!#% '!" % !"#%! $ %!757: 9?:-(%' A?1@>@A4 %%5#$ '!%$7 05694 ! !%#"* %#667 #$ %$6 05694 ! !%#"* % 667 #$ %$6 0
Slide 30: #(,(#&($#$&!-1'$&(&("#($ =1 2 ('((&'(#&3 4 05694…
#(,(#&($#$&!-1'$&(&("#($ =1 2 ('((&'(#&3 4 05694+!% % $%0 0$$- /!# =/60 "&!#"!% !" " ! "%&!%%" 4(.) " &)!$ ' %&)%
Slide 31: ")&'#% '#"& ")&'#% '# '>$!"3$" ">$!"3$" (&"&&) #$!"' (&"&& ) #$!"'
")&'#% '#"& ")&'#% '# '>$!"3$" ">$!"3$" (&"&&) #$!"' (&"&& ) #$!"' %')#'#>$!"3$" %%& %%& ''(>$!"3$"
Slide 32: - #%&($! -
- #%&($! -
Slide 33: 05694"!% %* !"%* %'%$%$%#! "%!#12+!$0#' %# $#"%! %'%*+…
05694"!% %* !"%* %'%$%$%#! "%!#12+!$0#' %# $#"%! %'%*+ %$0#' #$% ##!(%+ $%#! * &$#%! ! 289;7/$"%!('(&$#%($&-($#'( 3-4 '$(3$$'%,$11@
Slide 34: Vehicle 1nM E2 Fulvestrant OP-1250 Camizestrant Amcenestrant Giredestrant Rintodestrant Elacestrant ARV-471 Lasofo…
Vehicle 1nM E2 Fulvestrant OP-1250 Camizestrant Amcenestrant Giredestrant Rintodestrant Elacestrant ARV-471 Lasofoxifene Tamoxifen 0 20 40 60 80 100 120 140 160 180 200 CERANs partial AF1 agonists strong AF1 agonists MCF-7 Vehicle 1nM E2 Fulvestrant OP-1250 Camizestrant Amcenestrant Giredestrant
Slide 35: -1' #(*($(-85-9-(*(-. ! 1'#!- #(*(-9 -10 -9 -8 -7 -6 0 20 40
-1' #(*($(-85-9-(*(-. ! 1'#!- #(*(-9 -10 -9 -8 -7 -6 0 20 40 60 80 100 120 Log [M] Alkaline Phophatase Activity (%E2) full agonists on AF-1 partial agonists on AF-1 complete antagonists on AF-1 no E2 Emax (%E2) 90.0 88.1 84.1 49.1 20.9 9.0 7.4 7.1
Slide 36: #$&(-()'/289;7*'0)!*'(&#( %'(+& !! "- "!! …
#$&(-()'/289;7*'0)!*'(&#( %'(+& !! "- "!! 0;16/ &2 5944 <85 0457
Slide 37: ! 289;7 '"$#'(&(-(*(-# ('('' $!' --7576+ %## #$% ## %$%$$…
! 289;7 '"$#'(&(-(*(-# ('('' $!' --7576+ %## #$% ## %$%$$ !#%%&) 65!./67:5&&($%#%'#'!#+"-( )&'%"' "#)%'#!,"&%""!('"'6/:8<'(!#%&"""'%%" !# #B%&' "%%"!'&'
Olema Pharmaceuticals — Investor Presentation (May 2023) on 6ix